



primary issues™

Your Community For Issues That Matter in Primary Care

Peer-to-Peer. Issues. Insights. Innovations.

Evolving Since 1999

1 cme

Probiotics for GI Health in 2012: Issues and Updates



Learning Objectives

After participating in this educational activity, participants should be better able to

1. Differentiate among probiotics and their utility for specific GI issues
2. Counsel patients in clinical practice regarding probiotics utilizing current guidelines and evidence-based data

Introduction

Microbiota, often referred to as microflora, in the human gastrointestinal (GI) tract comprise a complex community of microorganisms that contribute to a variety of local and systemic functions vital to development and well-being. There is substantial interest in using probiotics to target the GI microbiota to promote health. Probiotics are defined by the Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO) as “live

microorganisms which when administered in adequate amounts confer a health benefit on the host.”[1] Prebiotics are different from probiotics. Prebiotics are not alive, are usually nondigestible carbohydrates present in foods, and provide health benefits indirectly by enhancing the growth or activity of beneficial microorganisms present in the digestive tract. Synbiotics combine a prebiotic and a probiotic.[2]

Over the last decade, probiotic use has grown rapidly.[2] In a recent survey of US physicians (86% of whom were gastroenterologists), 93% of respondents reported that at least some of their patients use probiotics.[3] The most commonly targeted conditions were irritable bowel syndrome (IBS), antibiotic associated diarrhea (AAD), *Clostridium difficile* (*C. difficile*) colitis, pouchitis, and ulcerative colitis.[3]

Moreover, the number of clinical trials assessing probiotics in humans also has increased substantially in recent years. A search for human clinical trials published in English in the PubMed database (<http://www.ncbi.nlm.nih.gov/sites/entrez>) showed that 240 articles (40 per year) were published from January 2000 through December 2005. During the subsequent five years (January 2006 through December 2010), the number more than doubled to 537 (107.4 per year), and in 2011 alone, there were 132 publications.

To assist patients in making informed decisions regarding the use of probiotics for GI health, clinicians should be aware of the similarities and differences among the growing number of probiotics available, and be knowledgeable regarding the current data and guidelines supporting their use. This review on the efficacy of probiotics in GI disorders is designed to provide guidance to primary care clinicians who wish to provide evidence-based probiotic information to their patients.

Probiotic Nomenclature and Dosing

Pre-test Question 1

Results from clinical trials assessing health benefits for one strain should be assumed to apply to only that strain unless there is evidence to the contrary.

- A. True
- B. False

Probiotic microbes are categorized by genus and species using standard taxonomy, with an alphanumeric designation to identify specific probiotic microbes to the strain level.[1,4] For example, with the strain *Lactobacillus acidophilus* ATCC4356, the genus is *Lactobacillus*, the species is *acidophilus*, and the strain designation is ATCC4356. Maintaining the strain designation is important since strains even of the same species can have different effects. In some cases, manufacturers use a trademarked name to indicate the strain. The majority of probiotics are strains of the genera *Lactobacillus* and *Bifidobacterium*, but other bacteria are also used (eg, *Streptococcus thermophilus*, *Enterococcus faecium*, *Propionibacterium freudenreichii* and *Bacillus coagulans*).[4] However, probiotics are not limited to bacteria. A probiotic called “*Saccharomyces boulardii*,” which is actually a variant of *Saccharomyces cerevisiae*, is a commonly used probiotic yeast. Products may contain one or more probiotic microbes. Dosing for probiotics is calculated in colony forming units (CFU), which indicate the number of viable microorganisms able to form a colony on an agar plate, and this is generally expressed in a specified amount of the product (eg, 10⁹ CFU/capsule or 1 billion CFU/gram). Because recommended doses vary depending on the strain or product, it is not possible to state

a “general dose” for probiotics; the dosage used in clinical practice should be based on human studies supporting the intended health benefit.[4]



Because health benefits of probiotics may be strain-specific, providing the genus, species, and strain for each probiotic organism is imperative in clinical publications as well as on product labels.

Regulation of Probiotics in the US

At present, the FDA may regulate a probiotic as a dietary supplement, food ingredient, medical food, or as a drug, depending on its intended use.[2] Currently, no probiotic is marketed as a drug in the US.[2,4]

Most probiotics are marketed in the US as dietary supplements or as food ingredients.[2] Probiotic supplements are available as capsules, powders, or drops. Probiotic foods are most commonly yogurts or other fermented milk products (eg, kefir), but other food formats also exist. Labels for foods or dietary supplements may claim how the product affects the structure or function of the body – FDA approval is not required for this type of claim, although the products are required by law to be labeled in a truthful and accurate fashion.[2,5] Claims that relate the probiotic to the cure, treatment, prevention, or mitigation of disease are not allowed in the US for a food or dietary supplement; such claims are limited to drugs.[2,4,6] However, claims that a product can reduce the risk of a disease are allowed with premarket approval.[7] Clinical data showing the efficacy of a probiotic in the treatment or prevention of disease may be available, but food or dietary supplement labels may not communicate that evidence.[6] For example, a manufacturer may state that a product improves transit time through the colon, as this is an effect on a normal body function, but not that the food or dietary supplement treats constipation, which is a disease. As a result, many of the claims cited on probiotic product labels are general and provide patients or clinicians with limited information about their potential use because they do not specifically relate to the studies that have been conducted.

Probiotics can also be marketed in the US as medical foods. The FDA defines a medical food as “a food which is formulated to be consumed or administered enterally under the supervision of a physician, and which is intended for the specific dietary management of a disease or condition for which distinctive nutritional requirements, based on recognized scientific principles, are established by medical evaluation.”[8] Medical foods are exempt from the labeling requirements for health claims and nutrient content claims.[8]



A medical food is intended for use under the supervision of a physician, whereas a dietary supplement can be used with or without supervision of a physician.

(Figure 1) illustrates the type of information that experts from the World Health Organization and International Scientific Association for Probiotics and Prebiotics (ISAPP) [1,6] consider to be important on probiotic product labels. Patients should be advised to choose products that provide complete information.

Figure 1. World Health Organization Recommended Label Information[6]

<p>EXPIRATION DATE</p>	<p>BRAND NAME <i>Genus species (strain)</i> For <u>all</u> microbes contained in the product</p>
<p>Colony forming units (CFUs): minimum number viable microorganisms at expiration date</p>	<p>Health Benefit (eg, improves GI transit time)</p>
<p>Contact us at: http://productwebsite.com Company Name Address Phone number</p>	<p>Suggested serving size or dose</p> <p><i>Proper storage conditions</i> (Climate changes, exposure to moisture and oxygen may be important to keep probiotics alive)</p>

Probiotic Mechanisms of Action

Microbiota are important to the development and maintenance of innate and adaptive immunity, digestive and metabolic actions, intestinal barrier integrity, and discouraging the colonization of pathogens.[9] The microbiota in healthy individuals over the age of 2 are relatively stable[9] but can be perturbed with different lifestyle exposures.[10] Colonization patterns common to humans have been identified, but each individual has a unique microbiota.

The make-up of microbiota may be altered by diet, medications, and illness. However, alterations in the microbiota in response to short-term dietary changes tend to be rapid, transient, and typically do not alter the overall composition of an individual's microbiota.[11] Results of two small studies suggest that antibiotic-associated changes in the human microbiota are not as quickly resolved. Dethlefsen, et al[12,13] followed outcomes in 3 patients through 2 courses of ciprofloxacin treatment. They found that antibiotic-induced changes were evident within 3 to 4 days after initiating ciprofloxacin.[13] While the overall pretreatment microbiota composition was somewhat restored after stopping the antibiotic, there was evidence that recovery was incomplete.[12,13] Some diseases (ie, inflammatory bowel diseases [IBD], metabolic disease, type 1 diabetes, allergy, asthma, neurological and cardiovascular disease)

are associated with microbiota that differ from the microbiota of healthy controls. However, it is not clear if these differences cause, or are the result of, the disease.[14]


Pre-test Question 2

Probiotics are thought to provide health benefits through all of the following mechanisms EXCEPT:

- A. Altering the microbiota through long-term colonization
- B. Directly inhibiting growth of pathogenic microorganisms
- C. Eliciting elaboration of anti-inflammatory cytokines
- D. Exerting neuromodulatory effects

Mechanisms, both established and hypothesized, of probiotic activity are shown in **(Figure 2)**. [15] Briefly, probiotics may act directly or indirectly on the colonizing gut microbiota, thereby positively impacting human health. Probiotics have been shown to inhibit the growth of pathogens through the production of antimicrobial substances, and to bolster the epithelial barrier function. They contribute to sustaining the host immune response and have metabolic and digestive functions, such as reducing cholesterol levels and synthesizing folate and vitamin B12. [16] Preclinical data have shown that probiotic microorganisms can have anti-inflammatory effects and may exert neuromodulatory effects that moderate response to stress. [17] In addition, these multiple mechanisms of action provide an explanation for many of the GI benefits observed, but may also explain the potential for numerous extra-intestinal benefits, such as reduction of incidence or duration of some acute respiratory diseases, [18] pain perception, [19] and improved therapeutic efficacy of drugs to treat bacterial vaginosis. [18,20]

Figure 2. Potential or known mechanisms of action of probiotics in the gut.[15]



The intestines are considered to be the site of most probiotic activity. For probiotics to survive transit into the colon, they need to be resistant to the extreme acidic environment of the stomach and the digestive secretions (bile and enzymes) in the proximal small intestine. Although most probiotics can survive intestinal transit, their effects require regular use because they generally colonize the digestive tract transiently.[17,21]

Evidence-Based Recommendations: Probiotics for GI Health

Because regulatory requirements for dietary supplements and foods require that products have demonstrated efficacy in the general (not patient) population, some studies of probiotics are designed with physiological, rather than clinical, endpoints. For example, a study may evaluate a probiotic's effects on colonic transit time in healthy people rather than on the relief of constipation. However, numerous examples of studies examining effects in patient populations can also be found in the literature.[22] The quality of these studies ranges broadly, but the literature in recent years comprises a greater number of well-designed, adequately powered, registered clinical trials (RCT).

Safety

Pre-test Question 3

Which of the following adverse events are routinely reported in $\geq 5\%$ of patients who use probiotics?

- A. Nausea and vomiting
- B. Diarrhea
- C. Flatulence and bloating
- D. All of the above
- E. None of the above

Given that many probiotic products contain naturally occurring microbes that are widely consumed in foods, historically many investigators did not see the need to track adverse events (AEs).[23] The inconsistent approach to safety reporting was noted in a recent report sponsored by the Agency for Healthcare Research and Quality (AHRQ).[24] They found no reports evaluating the safety of long-term probiotic use. In their review of 622 human short-term studies of probiotics, they found that the relative risk of any AE did not differ among groups that received probiotics versus controls. The analysis found no evidence for an increased risk for serious adverse events with concomitant probiotic and corticosteroid use.[24] The study group identified a total of 8 studies (including 3 case studies) that reported on patients taking both probiotics and immunosuppressive agents.[24] Two case series reported fungemia and one reported an abscess potentially associated with probiotic use. No strong safety signal was found in the analysis of RCTs.[24] These findings suggest that infections due to probiotic use are low even in this particularly vulnerable patient population.

A systematic review[25] of 72 publications that reported data from patients who required nutritional support found low rates of probiotic blood-stream infections. Risk factors for infections were the presence of a central venous catheter and immunosuppression.[25] Probiotic use in patients at high risk of severe acute pancreatitis was associated with higher mortality in one randomized controlled trial.[26] Therefore, probiotics should be used with caution in seriously ill patients.



In 622 short-term studies of probiotic administration, the incidence of adverse events in the probiotic groups was statistically similar to that of control groups.[24]

Current Recommendations for Use of Probiotics in GI Conditions

Updated guidelines for global probiotic use were issued by the World Gastroenterology Organization (WGO) in 2011.[4] A working group at the *Third Yale Workshop on Probiotic Use* also published recommendations for probiotic use in GI conditions the same year.[27] This review summarizes these recommendations for probiotic products marketed in the US.

WGO levels of evidence are defined as: 1a, systematic review with homogeneity of randomized controlled trials; 1b, individual randomized, controlled trial with narrow confidence interval; or, 2b, individual cohort study, including low-quality RCT.[4,17] Effectiveness ratings assigned by the Yale working group are defined as: A = strong, positive studies in the literature; B = based on positive controlled studies, but presence of some negative studies that did not support the primary outcome; C = some positive studies but clearly inadequate amount of work to establish certainty.[27] For the reader's convenience, a summary of these recommendations, including descriptions of rating scales, will be available for download at the end of this educational activity.

Acute Infectious Diarrhea

Pre-test Question 4

Which of the following statements is NOT a widely accepted approach to prevention and treatment of infectious diarrhea?

- A. *Lactobacillus* species reduce the risk of traveler's diarrhea
- B. *Lactobacillus rhamnosus* GG (Culturelle), *Lactobacillus reuteri* DSM 17938 (BioGaia) or *Lactobacillus casei* DN-114 001 (DanActive) taken routinely may reduce the risk of infectious diarrhea, especially in children
- C. Use of products containing *Lactobacillus rhamnosus* GG (Culturelle) or *Saccharomyces cerevisiae* boulardii (Florastor) may shorten the duration of acute infectious diarrhea in children and adults

Prevention of infectious diarrhea with probiotics has been evaluated in children. Studies show modest benefits from the use of *Lactobacillus rhamnosus* GG (LGG; Culturelle), *Lactobacillus reuteri* (*L. reuteri*) DSM 17938 (BioGaia) or *Lactobacillus casei* (*L. casei*) DN-114 001 (DanActive) to prevent pediatric acute infectious diarrhea.[17] The Yale group cites moderate support for prophylaxis with LGG (Culturelle) or *Saccharomyces cerevisiae* var. *boulardii* (*S. boulardii*; Florastor).[27] However, WGO guidelines state that additional studies are needed to confirm the benefit of these microorganisms for prevention of infectious diarrhea in children.[4] Whether results in children will translate to efficacy in adults remains to be determined, as fewer data are available regarding probiotics for the prevention of acute infectious diarrhea in adults.

Based on consistent data from several meta-analyses, the WGO recommends the use of LGG (Culturelle) and *S. boulardii* (Florastor) for the treatment of acute infectious diarrhea in children.[4] In addition to LGG (Culturelle) and *S. boulardii* (Florastor), the Yale group assigned an A effectiveness rating to *L. reuteri* DSM 17938 (BioGaia) for treatment of pediatric infectious diarrhea.[26] The American Academy of Pediatrics recommends starting children on LGG (Culturelle) early in the course of acute infectious diarrhea.[28] WGO recommendations support the use of *S. boulardii* (Florastor) to treat adult diarrhea.[4]

Travelers' Diarrhea

Travelers' diarrhea (TD) is a form of infectious diarrhea that may be caused by bacteria, viruses, or parasites.[29] Neither the WGO or the Yale Group specifically addresses probiotics for preventing traveler's diarrhea, and others have concluded that the evidence is insufficient for use of probiotics for this indication.[30] However, a 2007 meta-analysis of data from 12 studies showed a significant 15% reduction in risk of TD among probiotic users (RR=0.85, 95% CI 0.79 to 0.91).[31] Both *S. boulardii* (Florastor) and a mixture of *Lactobacillus acidophilus* (*L. acidophilus*) and *Bifidobacterium bifidum* (*B. bifidum*) were found to be beneficial in this analysis.[31] The mixture of *L. acidophilus* and *B. bifidum* is not marketed in the US. A separate analysis of two studies with *S. boulardii* (Florastor) found a lower risk of TD in subjects who started probiotic use 5 days before travel.[29]

Antibiotic-Associated Diarrhea

Pre-test Question 5

A 2 year old girl presents with irritability, fevers, and ear pain. You diagnose her with recurrent otitis media, and place her on amoxicillin and clavulanate for 10 days. The patient's mother is worried because she developed diarrhea the last time you put her on antibiotics. Which of the following options are evidence-based approaches?

- A. Start the antibiotic and have her consume regular yogurt
- B. Start the antibiotic and have the patient take *S. boulardii* (Florastor)
- C. Start the antibiotic and have the patient take a supplement with LGG (Culturelle)
- D. A and B
- E. B and C

According to the WGO Guidelines LGG (Culturelle) and *S. boulardii* (Florastor) are the most widely studied probiotics for the prevention and treatment of AAD and the overall results of those studies support their use in this setting.[4] However, *L. casei* DN-114 001 (DanActive) and the combination of *L. acidophilus* CL1285 and *L. casei* LBC80 (BioK+) also are recommended for adults.[4] A meta-analysis[32] published after the WGO guidelines were released confirmed these recommendations. Pooled results from 63 RCT (39 in outpatients) that included 11, 811 patients showed that patients who used adjunctive probiotics had a 42% lower risk of developing AAD (P<.001). This translates to a number-needed-to treat of 13. The analysis showed similar efficacy across all age groups (infants, children, and adults).[32]



The number of adults or children needed to treat with adjunctive probiotics to avoid one case of antibiotic-associated diarrhea is 13.[31]

Evidence of the benefit of probiotics for prevention of the most severe form of AAD, *C. difficile* diarrhea (CDD), remains equivocal. The WGO considered the evidence of benefit to be modest (1b) for *L. casei* DN-114 001 (DanActive), *S. boulardii* (Florastor), and a combination of *L. acidophilus* CL1285 and *L. casei* LBC80R (BioK+) for prevention of CDD.[4] The Yale group rated the effectiveness of *S. boulardii* (Florastor) as B/C. In a comprehensive review of studies evaluating individual probiotic products, Na and Kelly[33] concluded that studies from larger,

higher-quality trials are needed to determine efficacy in primary or secondary prevention of *C. difficile* infections.

Inflammatory Bowel Diseases

Pre-test Question 6

Current evidence does NOT support the use of any probiotic strains for:

- A. Crohn's disease
- B. Pouchitis
- C. Ulcerative colitis
- D. All of the above
- E. None of the above

Ulcerative Colitis

VSL#3 is the only probiotic currently marketed in the US that has been widely studied for the treatment or prevention of relapse in ulcerative colitis (UC). In two studies, patients with relapsing UC showed greater improvement in UC disease activity indices compared to placebo after treatment with high-dose VSL#3 (3.6 trillion CFU per day) added to standard therapy.[34,35] A small study (N=29) in children showed improved rates of response or remission with VSL#3 administration added to standard therapy compared to standard therapy alone.[36] Although a Cochrane review concluded there was not sufficient evidence to draw conclusions about the efficacy of probiotics for maintenance of remission of UC,[37] this review did not consider data for VSL#3 separately. The effectiveness of VSL#3 in maintaining remission of ulcerative colitis is rated A by the Yale group.[27] Studies of *E coli* Nissle 1917 have shown efficacy in maintaining remission of UC. However, this probiotic is no longer marketed in the US based on an FDA decision that this product did not meet the definition of a medical food but would have to be marketed as a biologic drug, a distinct category that must meet regulatory requirements for drugs.[17]

Pouchitis

Pouchitis is a post-surgical complication of ulcerative colitis. Both WGO guidelines and Yale group reports concur that VSL#3 is effective in the prevention of onset and relapse of pouchitis after induction of antibiotic therapy.[4,17] A single study found that LGG (Culturelle) treatment was effective in the prevention of first-onset pouchitis.[38]

Crohn's Disease

Several systematic reviews and meta-analyses have found no benefit of probiotics in the maintenance of remission for Crohn's disease.[39-42] Moreover, results from one meta-analysis suggested that administration of LGG (Culturelle) as maintenance therapy may increase the relapse rates of Crohn's disease.[41]



Several systematic reviews and meta-analyses found no benefit for probiotics in the maintenance of remission of Crohn's disease.[39-42]

Irritable Bowel Syndrome

Irritable bowel syndrome (IBS) is a functional GI disorder that may be associated predominantly with symptoms of diarrhea (IBS-D), constipation (IBS-C), or alternating. The WGO and Yale working group found the strongest support for the use of *Bifidobacterium infantis* (*B. infantis*) 35624 (Align) for the treatment of irritable bowel syndrome (IBS) in adults based on data from two randomized, double-blind, multicenter, placebo-controlled clinical trials.[43,44] A post-hoc analysis of data from one of these trials was undertaken to determine the impact of treatment with *B. infantis* 35624 on sub-types IBS-D or IBS-C. The analysis showed that satisfaction with bowel habits in subjects who took *B. infantis* 35624 was significantly improved compared to placebo.[44] This finding was true in both IBS-D and IBS-C patients. In patients with IBS-D, scores for overall symptom relief and the IBS composite score were significantly better with *B. infantis* 35624 (Align) treatment compared to placebo. Patients with IBS-C reported a statistically significant reduction in baseline abdominal pain/discomfort scores with treatment compared to placebo (-0.58, P=.036).[44]

The effects of consuming yogurt containing *Bifidobacterium animalis* subsp. *lactis* (*B. lactis*) DN-173 010 (Activia) was evaluated in two randomized controlled trials in adults with IBS-C. One 4-week study (n=34) reported a significantly greater reduction in overall IBS severity and abdominal pain in IBS-C subjects compared with control subjects.[45] A second study assessed efficacy using a Health Quality of Life Discomfort score in 274 IBS-C adults.[46] The *B. lactis* group was more likely to achieve a 10% decrease in baseline discomfort scores over 3 weeks compared with controls.[46] Although the WGO rated the evidence for *B. lactis* DN-173 010 (Activia) as 1b, the Yale group rated the effectiveness as C.[4,27]

Additional studies are needed to better elucidate the role of specific strains in treating IBS. However, since so few traditional treatment options exist for IBS, and probiotics have low rates of adverse events, a 3- to 4-week course of a specific probiotic product for managing IBS symptoms may be beneficial. If symptoms do not improve, it would be prudent to have a washout period for a few weeks and then try another probiotic strain.

Functional Bowel Disorders in Children

Of the products marketed in the US, the WGO found reasonably strong evidence to support the use of LGG (Culturelle) for symptomatic relief of functional bowel disorders in children.[4] This position is consistent with findings of a meta-analysis of data from three randomized controlled trials of children.[47] The pooled results showed that among children with IBS, those who received LGG (Culturelle) were significantly more likely to achieve response (no pain or a decrease in pain intensity) than those who received placebo.[47]

Lactose Intolerance

Eating yogurt containing live cultures may be beneficial for individuals who do not effectively digest lactose. Based on the findings of the European Food Safety Authority (EFSA),[48] WGO guidelines recommend consumption of yogurt containing 10^8 CFU per gram of *Lactobacillus delbruekii* subsp. *bulgaricus* (*L. bulgaricus*) and *Streptococcus thermophilus* (*S. thermophilus*) to reduce symptoms of lactose maldigestion.[4] *L. bulgaricus* and *S. thermophilus* are the standard starter cultures used for yogurt in the US, and the National Yogurt Association certifies that refrigerated products that carry their Live & Active Cultures seal contain 10^8 CFU of these two starter cultures per gram at the time of manufacture.[49]

Necrotizing Enterocolitis (NEC)

Necrotizing enterocolitis is a serious condition that sometimes develops in preterm infants. The WGO guidelines and the Yale group recommendations indicate that probiotic administration significantly reduces the incidence of NEC and mortality in preterm infants (level of evidence 1b/effectiveness B), albeit for probiotics not marketed in the US.[4,27] Mihatsch et al conducted a meta-analysis of data from 15 studies of *Lactobacillus* and *Bifidobacterium* species for prevention of NEC and sepsis.[50] The 2012 analysis concluded that although there is promising evidence of benefit in the setting of NEC, more studies are needed to clarify effective strains and doses before a general recommendation can be made.[50] Use of a live biotherapeutic in the highly susceptible premature infant is a concern for some practitioners.[51]

Future Directions in Probiotic Use

As the understanding of how probiotics interact with GI microbiota in health and disease continues to develop, there is hope that probiotics can be targeted to the patients and conditions that will benefit most. In addition to improving outcomes for individuals with difficult-to-treat GI symptoms, promising benefits beyond the gut may be realized. The metabolic and neuromodulatory effects of gut microorganisms may expand probiotic use in managing general immune-associated conditions such as common infectious diseases and allergy, as well as systemic conditions such as diabetes and obesity.[14] Animal studies, supported by some small human pilot trials, show that the microbiota have a profound effect on anxiety and stress.[10,52] Abdominal pain experienced by patients with IBS is attributed to visceral hypersensitivity. The heightened pain response is thought to be mediated by components of both the peripheral and central nervous systems.[53]

Conclusions

In the US, there is growing interest in the use of probiotics, and this review is designed to provide physicians with useful information to guide patient decisions about using probiotics for GI health. Currently probiotic products are marketed as dietary supplements and yogurts containing live cultures, as well as other foods. A combination of microorganisms (VSL#3) is sold as a medical food for use under the supervision of a physician. Although it is important for patients to read product labels, patients need to know that, legally, manufacturers of foods or supplements are not allowed to cite clinical evidence of efficacy for any disease. Claims of efficacy to cure or prevent a disease are limited to drugs. Patients who decide to use probiotics should be advised to use products that provide complete label information (**Figure 1**) including the genus, species, and strain for each organism the product contains. Moreover, they need to know that sustained use of probiotics is needed for chronic conditions; probiotics have not been shown to colonize the human gut.

The role of probiotics in managing a broad range of GI conditions has been supported by current evidence. Based on updated clinical guidelines, there is convincing evidence that probiotics available in the US may improve patient outcomes in treating infectious diarrhea, particularly in children, and preventing AAD. Further studies are needed to confirm the promise for other disorders, and strain-specific effects are important to consider. Short-term clinical trials have reported few serious adverse events associated with currently marketed probiotics.

Probiotics for GI Health in 2012: Issues and Updates

Table 1. World Gastroenterology Organization (WGO)¹ and Yale Probiotic Working Group² Recommendations Regarding Probiotics Marketed in the United States: Uses for GI Conditions. Probiotic use is not recommended for seriously ill patients.

INDICATION	GENUS/SPECIES/ STRAIN	PATIENT POPULATION: STRENGTH OF EVIDENCE ^A / EFFECTIVENESS ^B (Evidence-based dose)	COMMERCIAL PRODUCT/ PROPRIETARY MICROBE NAME/ MANUFACTURER'S RECOMMENDED DOSE	MANUFACTURER'S WEBSITE	COST/QUANTITY ^C
Prevention of Acute Infectious Diarrhea	<i>Lactobacillus rhamnosus</i> (GG)	Pediatrics: B	Culturelle 10x10 ⁹ CFU/ day To support digestive health and immune function 10x10 ⁹ CFU twice per day for digestive upset	http://www.culturelle.com/	\$18.52/30 capsules (1 x 10 ¹⁰ CFU/capsule); \$15.82/30 powder packets (1.5 x10 ⁹ CFU/packet)
	<i>Saccharomyces cerevisiae</i> var. boulardii	Pediatrics: B	Florastor Saccharomyces boulardii (lyophilized [lyo]) 250 mg <i>Contraindicated with central venous catheter</i>	http://florastor.com/	\$35.50/50 capsules (250 mg/capsule); \$19/10 powder packets (250 mg/packet)
Treatment of Acute Infectious Diarrhea	<i>Lactobacillus reuteri</i> (DSM 17938)	Pediatrics: A (10 ⁸ CFU twice daily)	BioGaia <i>Lactobacillus reuteri</i> protectis 1x10 ⁸ CFU/dose	http://www.childrensprobiotics.com/	\$39.50/ 50 mL; \$25.39/ 30 chewable tablets; \$29.99/30 straws
	<i>Lactobacillus rhamnosus</i> (GG)	Pediatrics: 1a/A (10 ¹⁰ -10 ¹¹ CFU twice daily) Adults 2b (10 ⁹ CFU twice daily)	Culturelle 10x10 ⁹ CFU/ day To support digestive health and immune function Twice per day for digestive upset	http://www.culturelle.com/	\$18.52/30 capsules (1 x 10 ¹⁰ CFU/capsule); \$15.82/30 powder packets (1.5 x10 ⁹ CFU/packet)
	<i>Saccharomyces cerevisiae</i> var. boulardii	Pediatrics: 1a/A (200 mg three times daily) Adults: 1b (10 ⁹ CFU per capsule of 250 mg, 2-6 capsules per day)	Florastor Saccharomyces boulardii (lyophilized [lyo]) 250 mg <i>Contraindicated with central venous catheter</i>	http://florastor.com/	\$35.50/50 capsules (250 mg/capsule); \$19/10 powder packets (250 mg/packet)
Prevention of Antibiotic-associated Diarrhea	<i>Lactobacillus acidophilus</i> (CL1285) and <i>Lactobacillus casei</i> (LBC80R)	Adult: 1b (5x10 ¹⁰ CFU once or twice daily)	BioK+ Cultured food or capsules	https://www.bioplus.com/en-us/home	Capsules available \$12.00/15 capsules (12.5 x10 ⁹ CFU/capsule); \$20.00/15 capsules (25 x10 ⁹ CFU/capsule); \$31.50/15 capsules (50 x10 ⁹ CFU/capsule)
	<i>Lactobacillus casei</i> (DN-114 001)	Adult: 1b/A (10 ¹⁰ CFU twice daily)	DanActive Lactobacillus immunitas Plus starter cultures Yogurt or cultured food ^d	http://www.dannon.com/ourproducts.aspx	Price varies by store
	<i>Lactobacillus rhamnosus</i> (GG)	Pediatrics: 1b/A (10 ¹⁰ CFU once or twice daily) Adult: 1b (10 ¹⁰ - 10 ¹¹ CFU twice daily)	Culturelle 10x10 ⁹ CFU/day To support digestive health and immune function 10x10 ⁹ CFU/twice per day for digestive upset	http://www.culturelle.com/	\$18.52/30 capsules (1 x 10 ¹⁰ CFU/capsule); \$15.82/30 powder packets (1.5 x10 ⁹ CFU/packet)
	<i>Saccharomyces cerevisiae</i> var. boulardii	Pediatrics: 1a/A (250 mg twice daily) Adults: 1b (1 g or 4x10 ⁹ CFU daily)	Florastor Saccharomyces boulardii (lyophilized [lyo]) 250 mg <i>Contraindicated with central venous catheter</i>	http://florastor.com/	\$35.50/50 capsules (250 mg/capsule); \$19/10 powder packets (250 mg/packet)

Disclaimer: It is hoped that information in this activity will be useful in the management of your patients. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, review of any applicable manufacturers' product information, and comparison with recommendations of recognized authorities. The information in this activity is provided to medical professionals for information purposes only. It is NOT to be disseminated to patients or for any other purpose. In particular, no information contained within this activity is intended to be used for medical diagnosis or treatment.

Probiotics for GI Health in 2012: Issues and Updates

INDICATION	GENUS/SPECIES/ STRAIN	PATIENT POPULATION: STRENGTH OF EVIDENCE ^a / EFFECTIVENESS ^b (Evidence-based dose)	COMMERCIAL PRODUCT/ PROPRIETARY MICROBE NAME/ MANUFACTURER'S RECOMMENDED DOSE	MANUFACTURER'S WEBSITE	COST/QUANTITY ^c
Prevention of <i>C. difficile</i> diarrhea	<i>Lactobacillus acidophilus</i> (CL1285) and <i>Lactobacillus casei</i> (LBC80R)	Adult: 1b (5x10 ⁹ CFU once or twice daily)	BioK+ Cultured food or capsules	https://www.biokplus.com/en-us/home	\$12.00/15 capsules (12.5 x10 ⁹ CFU/capsule); \$20.00/15 capsules (25 x10 ⁹ CFU/capsule); \$31.50/15 capsules (50 x10 ⁹ CFU/capsule)
	<i>Lactobacillus casei</i> (DN-114 001)	Adult: 1b (10 ¹⁰ CFU twice daily)	DanActive Lactobacillus immunitas Yogurt or cultured food ^d	http://www.dannon.com/ourproducts.aspx	Price varies by store
	<i>Lactobacillus rhamnosus</i> (GG)	Adult: B/C	Culturelle 10x10 ⁹ CFU/ day To support digestive health and immune function 10x10 ⁹ CFU/ twice per day for digestive upset	http://www.culturelle.com/	\$18.52/30 capsules (1 x 10 ¹⁰ CFU/capsule); \$15.82/30 powder packets (1.5 x10 ⁹ CFU/packet)
	<i>Saccharomyces cerevisiae</i> var. bouldarii	Adult: 1b/B/C (2-3 x10 ⁹ CFU daily for 28 days, followed for another 4 weeks)	Florastor Saccharomyces boulardii (lyophilized [Iyo]) 250 mg <i>Contraindicated with central venous catheter</i>	http://florastor.com/	\$35.50/50 capsules (250 mg/capsule); \$19/10 powder packets (250 mg/packet)
Inflammatory Bowel Diseases (IBD) Treatment of mildly active UC or pouchitis	<i>Bifidobacterium breve</i> , <i>Bifidobacterium longum</i> , <i>Bifidobacterium infantis</i> , <i>Lactobacillus acidophilus</i> , <i>Lactobacillus plantarum</i> , <i>Lactobacillus paracasei</i> , <i>Lactobacillus bulgaricus</i> , <i>Streptococcus thermophilus</i>	Pediatrics: 1b (4-9x10 ¹¹ CFU twice daily)	VSL#3 <i>For use under the supervision of a physician</i> (Strains not indicated on product)	http://www.vsl3.com/	Capsules that contain 112.5 billion live bacteria \$54/60 capsules (\$7.20/2x 9x10 ¹¹ CFU dose); Packets that contain 450 billion live bacteria \$86/ 30 packets (\$5.73/2x9x10 ¹¹ CFU dose); Double Strength (DS) packets that contain 900 billion live bacte- ria. Price not given
Adults: 1b (2-9x10 ¹¹ CFU twice daily)					
Pouchitis: C UC: B					
Adults: 1b/A (9x10 ¹¹ CFU twice daily)					
IBD Induction of remission		Adults: C UC: B			
IBD Prevention and maintenance of remission of pouchitis		Adults: 1b/A (9x10 ¹¹ CFU twice daily)			
IBD Maintenance of remission of ulcerative colitis		Adults: A			
Irritable Bowel Syndrome Symptomatic relief	<i>Bifidobacterium infantis</i> (35624)	Adults: 1b/B (10 ⁸ CFU once daily)	Align Bifantis 1x10 ⁹ CFU/ day As 1 capsule	http://www.alinggi.com/	\$44.99/42 capsules (\$1.07/capsule)
	<i>Bifidobacterium animalis</i> subsp. <i>lactis</i> (DN-173 010) + starter cultures	Adults: 1b/C (10 ¹⁰ CFU twice daily)	Activia Bifidobacterium regularis Yogurt ^d	http://activia.us.com/	Price varies by store
Pediatric functional bowel disorders- Symptomatic relief	<i>Lactobacillus reuteri</i> DSM 17938	Pediatrics: 1b (10 ⁸ CFU twice daily)	BioGaia <i>Lactobacillus reuteri</i> protectis 1x10 ⁸ CFU/dose	http://www.childrensprobiotics.com/	\$39.50/50 mL (107 CFU/5 drops); \$25.39/30 chewable tablets (107 CFU/tablet); \$29.99/30 straws (107 CFU/straw)
	<i>Lactobacillus rhamnosus</i> (GG)	Pediatrics: 1a (10 ¹⁰ -10 ¹¹ CFU twice daily)	Culturelle 10x10 ⁹ CFU/day To support digestive health and immune function 10x10 ⁹ CFU twice per day for digestive upset	http://www.culturelle.com/	\$18.52/30 capsules (1 x 10 ¹⁰ CFU/capsule); \$15.82/30 powder packets (1.5 x10 ⁹ CFU/packet)

Disclaimer: It is hoped that information in this activity will be useful in the management of your patients. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients' conditions, review of any applicable manufacturers' product information, and comparison with recommendations of recognized authorities. The information in this activity is provided to medical professionals for information purposes only. It is NOT to be disseminated to patients or for any other purpose. In particular, no information contained within this activity is intended to be used for medical diagnosis or treatment.

Probiotics for GI Health in 2012: Issues and Updates

^aWorld Gastroenterology Organization (WGO) levels of evidence are defined as: 1a, systematic review with homogeneity of randomized controlled trials; 1b = individual randomized, controlled trial with narrow confidence interval; or 2b, individual cohort study, including low-quality RCT

^bEffectiveness ratings assigned by the Yale working group are defined as: A = strong, positive studies in the literature; B = based on positive controlled studies, but presence of some negative studies that did not support the primary outcome; C = some positive studies but clearly inadequate amount of work to establish certainty

^cPrices were taken from various websites for US distributors on August 16, 2012

^dThe CFU/per serving is not available for some yogurts and fermented milk preparations. Patients may wish to try consuming 2 to 3 servings a day and adjust their dose as needed

¹Guarner F, Khan AG, Garisch J, et al. World Gastroenterology Organisation Global Guidelines:Probiotics and prebiotics, October 2011. *J Clin Gastroenterol.* 2012;46(6):468-481. Available at http://www.worldgastroenterology.org/assets/export/userfiles/Probiotics_FINAL_20110116.pdf.

²Floch MH, Walker WA, Madsen K, et al. Recommendations for probiotic use-2011 update. *J Clin Gastroenterol.* 2011;45 Suppl:S168-171.

Content Disclaimer: The authors are exclusively responsible for the respective content. Accordingly, no responsibility is assumed by the contributing faculty, educational grant providers, and Primary Care Network and its affiliates associated with this activity for any injury and/or damage to persons or property as a matter of product liability, negligence or otherwise; or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without medically appropriate (1) evaluation of (a) their patients' conditions and (b) indications and possible contraindications, warnings, and adverse effects or dangers in use; (2) review of any applicable manufacturers' prescribing and other product information; (3) comparison with recommendations of recognized authorities; and (4) independent verification of diagnostic methods, therapeutic methods, results of research, and measurement of medical doses.

References

1. Report of a Joint FAO/WHO Expert Consultation on *Evaluation of Health and Properties of Probiotics in Food Including Powder Milk with Live Lactic Acid Bacteria*. Córdoba, Argentina, October 1-4, 2001. http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf Accessed July 24, 2012.
2. National Center for Complementary and Alternative Medicine. Oral probiotics: An introduction. <http://nccam.nih.gov/health/probiotics/introduction.htm>. Updated November 2011. Accessed July 24, 2012.
3. Williams MD, Ha CY, Ciorba MA. Probiotics as therapy in gastroenterology: a study of physician opinions and recommendations. *J Clin Gastroenterol*. 2010;44(9):631-636.
4. Guarner F, Khan AG, Garisch J, et al. World gastroenterology organisation global guidelines: probiotics and prebiotics, October 2011. *J Clin Gastroenterol*. 2012;46(6):468-481. Available at http://www.worldgastroenterology.org/assets/export/userfiles/Probiotics_FINAL_20110116.pdf.
5. National Center for Complementary and Alternative Medicine. Using dietary supplements wisely. <http://nccam.nih.gov/health/supplements/wiseseuse.htm>. Updated March 2011. Accessed July 24, 2012.
6. International Scientific Association for Probiotics and Prebiotics. Proiotics: A consumer guide to making smart choices. www.isapp.net. Updated March 11, 2009. Accessed July 16, 2012.
7. Sanders ME, Heimbach JT, Pot B, et al. Health claims substantiation for probiotic and prebiotic products. *Gut Microbes*. 2011;2(3):127-133.
8. United States Food and Drug Administration. Medical Foods. *Guidance for industry: frequently asked questions about medical foods*. <http://www.fda.gov/Food/GuidanceComplianceRegulatoryInformation/GuidanceDocuments/MedicalFoods/ucm054048.htm>. Updated July 27 2011. Accessed July 24, 2012.
9. Dave M, Higgins PD, Middha S, Rioux KP. The human gut microbiome: current knowledge, challenges, and future directions. *Transl Res*. 2012. Epub Jun 7. DOI: 10.1016/j.trsl.2012.05.003.
10. Neish AS. Microbes in gastrointestinal health and disease. *Gastroenterology*. 2009;136(1):65-80.
11. Wu GD, Chen J, Hoffmann C, et al. Linking long-term dietary patterns with gut microbial enterotypes. *Science*. 2011;334(6052):105-108.
12. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. *PLoS biology*. 2008;6(11):e280.
13. Dethlefsen L, Relman DA. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. *Proc Natl Acad Sci USA*. 2011;108 Suppl 1:4554-4561.
14. Blumberg R, Powrie F. Microbiota, disease, and back to health: a metastable journey. *Science Transl Med*. Jun 6 2012;4(137):137rv137.
15. O'Toole PW, Cooney JC. Probiotic bacteria influence the composition and function of the intestinal microbiota. *Interdisciplinary perspectives on infectious diseases*. 2008;2008:175285.
16. Holmes E, Kinross J, Gibson GR, et al. Therapeutic modulation of microbiota-host metabolic interactions. *Science Transl Med*. 2012;4(137):137rv136.
17. Ciorba MA. A Gastroenterologist's Guide to Probiotics. *Clin Gastroenterol Hepatol*. 2012 10(9):960-968.
18. Lenoir-Wijnkoop I, Sanders ME, Cabana MD, et al. Probiotic and prebiotic influence beyond the intestinal tract. *Nutr Rev*. 2007;65(11):469-489.
19. Konturek PC, Brzozowski T, Konturek SJ. Stress and the gut: pathophysiology, clinical consequences, diagnostic approach and treatment options. *J Physiol Pharmacol*. 2011;62(6):591-599.

20. Senok AC, Verstraelen H, Temmerman M, Botta GA. Probiotics for the treatment of bacterial vaginosis. *Cochrane Database Syst Rev.* 2009(4):CD006289.
21. Sanders ME. Impact of probiotics on colonizing microbiota of the gut. *J Clin Gastroenterol.* 2011;45 Suppl:S115-S119.
22. Shane AL, Cabana MD, Vidry S, et al. Guide to designing, conducting, publishing and communicating results of clinical studies involving probiotic applications in human participants. *Gut Microbes.* 2010;1(4):243-253.
23. Wallace TC, MacKay D. The safety of probiotics: considerations following the 2011 U.S. Agency for Health Research and Quality report. *J Nutri.* 2011;141(11):1923-1924.
24. Hempel S, Newberry S, Ruelaz A, et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evidence Report/Technology Assessment No. 200. 2011; www.ahrq.gov/clinic/tp/probiotictp.htm. Accessed August 15, 2012.
25. Whelan K, Myers CE. Safety of probiotics in patients receiving nutritional support: a systematic review of case reports, randomized controlled trials, and nonrandomized trials. *Am J Clin Nutr.* 2010;91(3):687-703.
26. Besselink MG, van Santvoort HC, Buskens E, et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. *Lancet.* 2008;371(9613):651-659.
27. Floch MH, Walker WA, Madsen K, et al. Recommendations for probiotic use-2011 update. *J Clin Gastroenterol.* 2011;45 Suppl:S168-S171.
28. Thomas DW, Greer FR, American Academy of Pediatrics Committee on Nutrition, et al. Probiotics and prebiotics in pediatrics. *Pediatrics.* Dec2010;126(6):1217-1231.
29. McFarland LV. Systematic review and meta-analysis of *Saccharomyces boulardii* in adult patients. *World J Gastroenterol.* 2010;16(18):2202-2222.
30. Ringel Y, Quigley EMM, Lin HC. Using probiotics in gastrointestinal disorders. *Am J Gastroenterol Suppl.* 2012;1(1):34-40.
31. McFarland LV. Meta-analysis of probiotics for the prevention of traveler's diarrhea. *Travel Med Infect Dis.* 2007;5(2):97-105.
32. Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. *JAMA.* 2012;307(18):1959-1969.
33. Na X, Kelly C. Probiotics in clostridium difficile Infection. *J Clin Gastroenterol.* 2011;45 Suppl:S154-158.
34. Sood A, Midha V, Makharia GK, et al. The probiotic preparation, VSL#3 induces remission in patients with mild-to-moderately active ulcerative colitis. *Clin Gastroenterol Hepatol.* 2009;7(11):1202-1209, 1209 e1201.
35. Tursi A, Brandimarte G, Papa A, et al. Treatment of relapsing mild-to-moderate ulcerative colitis with the probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. *Am J Gastroenterol.* 2010;105(10):2218-2227.
36. Miele E, Pascarella F, Giannetti E, Quaglietta L, Baldassano RN, Staiano A. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. *Am J Gastroenterol.* 2009;104(2):437-443.
37. Naidoo K, Gordon M, Fagbemi AO, Thomas AG, Akobeng AK. Probiotics for maintenance of remission in ulcerative colitis. *Cochrane Database Syst Rev.* 2011(12):CD007443.
38. Gosselink MP, Schouten WR, van Lieshout LM, Hop WC, Laman JD, Ruseler-van Embden JG. Delay of the first onset of pouchitis by oral intake of the probiotic strain *Lactobacillus rhamnosus* GG. *Dis Colon Rectum.* 2004;47(6):876-884.

39. Doherty G, Bennett G, Patil S, Cheifetz A, Moss AC. Interventions for prevention of post-operative recurrence of Crohn's disease. *Cochrane Database Syst Rev.* 2009(4):CD006873.
40. Rahimi R, Nikfar S, Rahimi F, et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. *Dig Dis Sci.* 2008;53(9):2524-2531.
41. Shen J, Ran HZ, Yin MH, Zhou TX, Xiao DS. Meta-analysis: the effect and adverse events of Lactobacilli versus placebo in maintenance therapy for Crohn disease. *Intern Med J.* 2009;39(2):103-109.
42. Rolfe VE, Fortun PJ, Hawkey CJ, Bath-Hextall F. Probiotics for maintenance of remission in Crohn's disease. *Cochrane Database Syst Rev.* 2006(4):CD004826.
43. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. *Gastroenterology.* 2005;128(3):541-551.
44. Whorwell PJ, Altringer L, Morel J, et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. *Am J Gastroenterol.* 2006;101(7):1581-1590.
45. Agrawal A, Houghton LA, Morris J, et al. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. *Aliment Pharmacol Ther.* 2009;29(1):104-114.
46. Guyonnet D, Chassany O, Ducrotte P, et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. *Aliment Pharmacol Ther.* 2007;26(3):475-486.
47. Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. *Aliment Pharmacol Ther.* 2011;33(12):1302-1310.
48. Panel EFSA on Dietetic Products, Nutrition and Allergies (NDA). Scientific opinion on the substantiation of health claims related to live yoghurt cultures and improved lactose digestion (ID 1143, 2976) pursuant to Article 13(1) of Regulation (EC) No 1924/2006. *Euro Food Safety Auth J.* 2010;8:1763-1781.
49. National Yogurt Council. About yogurt. <http://aboutyogurt.com/index.asp?bid=28#Q6>. Accessed August 4, 2012.
50. Mihatsch WA, Braegger CP, Decsi T, et al. Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. *Clinical Nutri.* 2012;31(1):6-15.
51. Neu J. Routine probiotics for premature infants: let's be careful! *J Ped.* 2011;158(4):672-674.
52. Grenham S, Clarke G, Cryan JF, Dinan TG. Brain-gut-microbe communication in health and disease. *Front Physiol.* 2011;2:94. Epub Dec. 7.
53. Fichna J, Storr MA. Brain-Gut Interactions in IBS. *Front Pharmacol.* 2012;3:127.